Drug intelligence / Profile preview

HLK-R047

Development stage: Preclinical
Lead developer: Shenzhen Yaoxin Biotechnology
Modality: Small Molecules
Administration: Topical

Overview

HLK-R047 is a preclinical-stage topical therapeutic candidate being developed by Shenzhen Yaoxin Biotechnology for the treatment of androgenetic alopecia (AGA). The drug is part of the company's pipeline focused on dermatological conditions and utilizes a topical formulation to target hair loss directly at the scalp. While the specific molecular target and mechanism of action have not been publicly disclosed by the sponsor, the asset is designed to address the underlying pathology of male and female pattern baldness. As of August 2026, HLK-R047 remains in the preclinical phase of development.

Beyond the preview

Go deeper on HLK-R047.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HLK-R047.

Explore the full profile